These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1571 related articles for article (PubMed ID: 10955825)

  • 1. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
    Swami S; Krishnan AV; Feldman D
    Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
    Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
    Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of estrogen receptor-alpha gene expression by 1, 25-dihydroxyvitamin D in MCF-7 cells.
    Stoica A; Saceda M; Fakhro A; Solomon HB; Fenster BD; Martin MB
    J Cell Biochem; 1999 Dec; 75(4):640-51. PubMed ID: 10572247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of epidermal growth factor receptor levels by 1,25-dihydroxyvitamin D3 in human breast cancer cells.
    Koga M; Eisman JA; Sutherland RL
    Cancer Res; 1988 May; 48(10):2734-9. PubMed ID: 2834048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein.
    Rubin M; Fenig E; Rosenauer A; Menendez-Botet C; Achkar C; Bentel JM; Yahalom J; Mendelsohn J; Miller WH
    Cancer Res; 1994 Dec; 54(24):6549-56. PubMed ID: 7987855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines.
    Elstner E; Linker-Israeli M; Said J; Umiel T; de Vos S; Shintaku IP; Heber D; Binderup L; Uskokovic M; Koeffler HP
    Cancer Res; 1995 Jul; 55(13):2822-30. PubMed ID: 7796409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
    Kinoshita Y; Chen S
    Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells.
    Liu ZJ; Zhu BT
    J Steroid Biochem Mol Biol; 2004 Mar; 88(3):265-75. PubMed ID: 15120420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
    Pink JJ; Jordan VC
    Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An adenosine analogue, IB-MECA, down-regulates estrogen receptor alpha and suppresses human breast cancer cell proliferation.
    Lu J; Pierron A; Ravid K
    Cancer Res; 2003 Oct; 63(19):6413-23. PubMed ID: 14559831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 1 alpha blocks estradiol-stimulated growth and down-regulates the estrogen receptor in MCF-7 breast cancer cells in vitro.
    Danforth DN; Sgagias MK
    Cancer Res; 1991 Mar; 51(5):1488-93. PubMed ID: 1997187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
    Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
    Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells.
    Lee YR; Park J; Yu HN; Kim JS; Youn HJ; Jung SH
    Biochem Biophys Res Commun; 2005 Nov; 336(4):1221-6. PubMed ID: 16169518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells.
    Kawai H; Li H; Chun P; Avraham S; Avraham HK
    Oncogene; 2002 Oct; 21(50):7730-9. PubMed ID: 12400015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
    Morrissey JJ; Raney S
    Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells.
    Girgert R; Hanf V; Emons G; Gründker C
    J Pineal Res; 2009 Aug; 47(1):23-31. PubMed ID: 19522736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells.
    Myrthue A; Rademacher BL; Pittsenbarger J; Kutyba-Brooks B; Gantner M; Qian DZ; Beer TM
    Clin Cancer Res; 2008 Jun; 14(11):3562-70. PubMed ID: 18519790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 17beta-Estradiol inhibits osteoprotegerin production by the estrogen receptor-alpha-positive human breast cancer cell line MCF-7.
    Rachner TD; Schoppet M; Niebergall U; Hofbauer LC
    Biochem Biophys Res Commun; 2008 Apr; 368(3):736-41. PubMed ID: 18252198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiestrogen potentiation of antiproliferative effects of vitamin D3 analogues in breast cancer cells.
    Love-Schimenti CD; Gibson DF; Ratnam AV; Bikle DD
    Cancer Res; 1996 Jun; 56(12):2789-94. PubMed ID: 8665515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
    Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
    Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.